Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease

NCT: NCT07557706 · RECRUITING

NCT IDNCT07557706
StatusRECRUITING
Start Date2025-09-15
Completion2026-12-31

Brief Summary

The purpose of this study is to find out whether a type of gentle nerve stimulation, called transcutaneous auricular Vagus Nerve Stimulation (taVNS), can help improve how the body regulates heart rate and blood pressure in people with Parkinson's Disease (PD). Problems with heart rate and blood pressure control are common and can make it harder for people to exercise or do daily activities. By using this non-invasive form of nerve stimulation and testing how it affects the body's natural responses, this study hopes to learn if taVNS could be a helpful tool to support physical therapy and improve overall function.

Frequently Asked Questions

What is Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease?

Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease is a clinical trial registered under NCT07557706. Current status: RECRUITING.

What is the status of NCT07557706?

The current status of NCT07557706 (Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease) is: RECRUITING.

When did Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease start?

Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease started on 2025-09-15.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑